Modulators of Nuclear Transport, for example, inhibitors of CRM1 and, More specifically, a compound represented by Structural formula (1),Or one of its pharmaceutically acceptable Salts.Synthesis and use of a compound of Structural formula (1) or a pharmaceutically acceptable Salt thereof, or a composition, for example, in treatment,The modulation and / or prevention of diseases associated with the Physiological Activity of CRM1.Claim 1: a compound of Structural formula (1) or one of its pharmaceutically acceptable salts, in which: R1 is selected from Hydrogen and methyl； R2 is selected from pyridin - 2 - iloPyridin - 3 - 4 - pyridin - ILO, ILO, pirazin thiocyanatoacetate, and quinoxalin - 2 - 4 - Ilo Ilo, pyrimidine, dioxotetrahidrotiofen - 3 - 1.1 - ILO and ciclopropilo,The R2 is optionally substituted with one or more substituents selected independently between Halogen or Methyl； R1 and R2 are taken together with its Atoms to form Intermediate 4 - HYDOxipiperidin - 1 - 1 - pyrrolidin-3-yl - ILO, ILO, ILO Azepan - 1 -, 4 - bencilpiperazin - yl - 1, 4 - etilpiperazin - 1 - iloHidroxiazetidin - 1 - 3 - or 4 - (Ilo Ilo； R3 is selected from Hydrogen and Halo, and the Wavy Line represents a single link.In which a Carbon Carbon Double Bonds attached to the same Configuration is in (e) and (Z).Moduladores del transporte nuclear, por ejemplo, a inhibidores de CRM1 y, más concretamente, a un compuesto representado por la fórmula estructural (1), o una de sus sales farmacéuticamente aceptables. Síntesis y el uso de un compuesto de fórmula estructural (1), o una sal farmacéuticamente aceptable o una composición del mismo, por ejemplo, en el tratamiento, la modulación y/o la prevención de afecciones fisiológicas asociadas con la actividad de CRM1.Reivindicación 1: Un compuesto de fórmula estructural (1) o una de sus sales farmacéuticamente aceptables, en la que: R1 se selecciona entre hidrógeno y metilo； R2 se selecciona entre piridin-2-ilo, piridin-3-ilo, piridin-4-ilo, pir
